Xiamen Amoytop Biotech Co., Ltd.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-19
ACTIVE TRIALS5
PHASE 3 / 2-33
RECRUITING5
READOUTS ≤12 MONTHS0
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Peginterferon α-2b injection NCT06552429 |
P2 | Recruiting | Essential Thrombocythemia | 27 | 2025-10-26 |
| Inpegsomatropin Injection NCT06927310 |
P3 | Recruiting | Idiopathic Short Stature | 300 | 2026-03 |
| Inpegsomatropin Injection NCT07551804 |
P2 | Recruiting | Adult Growth Hormone Deficiency | 36 | 2027-12-31 |
| Inpegsomatropin Injection NCT07309562 |
P3 | Recruiting | Small for Gestational Age | 141 | 2028-03 |
| Inpegsomatropin-Injection NCT07614152 |
P3 | Recruiting | Turner Syndrome | 84 | 2028-03-30 |